WELCOME TO NEUREN PHARMACEUTICALS'
Angelman SYNDROME STUDY
The purpose of the study is to look at the safety, tolerability, and effectiveness of NNZ-2591 in the treatment of children…
This clinical study is sponsored by Neuren Pharmaceuticals, a biopharmaceutical company headquartered in Melbourne…
The Angelman Syndrome Study has three locations across Australia, click here for details and contact details to connect with each location.
Does someone you know have Angelman syndrome ?
They may be eligible to participate in a research study on a new medication for children and adolescents aged 3-17 years.
Angelman syndrome is a genetically determined neurological disorder, characterized by speech delay, developmental delay, impairments in walking or problems with coordination, intellectual disability, seizures, or sleep disorder.
This is a spectrum disorder which means not all people display the same behaviors and symptoms.
People with Angelman syndrome need continuous care and are unable to live independently.
There is currently no treatment for Angelman syndrome.